RxSight, Inc. (NASDAQ:RXST) Short Interest Update

RxSight, Inc. (NASDAQ:RXST) saw a significant drop in short interest in January. As of January 30th, there was short interest totaling 4,144,635 shares, a drop of 13.4% from the January 15th total of 4,783,862 shares. Approximately 11.1% of the company’s stock are short sold. Based on an average trading volume of 1,128,003 shares, the short-interest ratio is currently 3.7 days. Based on an average trading volume of 1,128,003 shares, the short-interest ratio is currently 3.7 days. Approximately 11.1% of the company’s stock are short sold.

RxSight Price Performance

NASDAQ:RXST traded up $0.28 during mid-day trading on Tuesday, reaching $8.32. The stock had a trading volume of 42,537 shares, compared to its average volume of 1,083,736. The stock has a market cap of $342.04 million, a P/E ratio of -9.48 and a beta of 1.14. The business’s 50 day moving average is $10.09 and its 200 day moving average is $9.45. RxSight has a fifty-two week low of $6.32 and a fifty-two week high of $31.78.

Institutional Investors Weigh In On RxSight

Hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of RxSight by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock worth $552,000 after buying an additional 1,232 shares during the last quarter. Verition Fund Management LLC lifted its stake in RxSight by 4.4% during the fourth quarter. Verition Fund Management LLC now owns 40,613 shares of the company’s stock worth $423,000 after purchasing an additional 1,701 shares during the period. Larson Financial Group LLC boosted its stake in RxSight by 110.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of RxSight by 5.0% in the 2nd quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock worth $579,000 after purchasing an additional 2,121 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of RxSight during the second quarter worth approximately $28,000. 78.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

RXST has been the topic of several recent analyst reports. Wolfe Research raised shares of RxSight to an “outperform” rating in a report on Friday, January 30th. Piper Sandler upped their target price on shares of RxSight from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, January 20th. Stifel Nicolaus set a $10.00 price target on RxSight in a research note on Thursday, November 6th. Needham & Company LLC lifted their target price on RxSight from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, UBS Group reissued a “neutral” rating on shares of RxSight in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, RxSight currently has a consensus rating of “Reduce” and an average price target of $9.78.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.